论文部分内容阅读
SLE患者常伴有血栓症等凝血及纤溶异常,以往的实验室检查指标常缺乏特异性和敏感度.有关患SLE时血栓症的发病机理与凝血纤溶检查间关系尚未见报导.近年来,可测定通过凝血酶作用从纤维蛋白原游离出的纤维蛋白肽A(FPA)和通过纤维蛋白溶酶作用从纤维蛋白Ⅱ游离出的纤维蛋白肽Bβ15-42(FPBβ),较以往的凝血纤溶系统检查更敏感,可作为凝血纤溶系统的一个标记物.作者对合并血栓症的SLE患者的FPA和FPBβ进行了测定,并研究了与SLE疾病的关系.
SLE patients often accompanied by coagulation and fibrinolysis thrombosis abnormalities, laboratory tests often lack the specificity and sensitivity of the past .There is a relationship between the pathogenesis of thrombosis SLE and coagulation fibrinolysis has not been reported .In recent years , Fibrinopeptide A (FPA) released from fibrinogen by thrombin action and fibrin peptide B? 15-42 (FPB?) Released from fibrin II by the action of plasmin can be measured. Compared with conventional coagulation fibers Soluble system tests are more sensitive and can be used as a marker of the coagulation and fibrinolysis system.The authors measured FPA and FPBβ in patients with SLE with thrombosis and examined the relationship with SLE disease.